<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253276</url>
  </required_header>
  <id_info>
    <org_study_id>OCAPBC</org_study_id>
    <nct_id>NCT03253276</nct_id>
  </id_info>
  <brief_title>Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT</brief_title>
  <official_title>Effect of Obeticholic Acid (INT-747, Intercept) on the Hepatobiliary Transport of Bile Acids in Patients With PBC Examined by 11C-cholyl-sarcosine PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, double-blind crossover study on the mechanism of OCA&#xD;
      treatment of patients with PBC.&#xD;
&#xD;
      Hypothesis and significance&#xD;
&#xD;
      The investigators will test the hypothesis that OCA administration to patients with PBC&#xD;
      increases hepatobiliary secretion of cholylsarcosine assessed by PET/CT using 11C-labeled&#xD;
      cholylsarcosine (11C-CSar) as tracer.&#xD;
&#xD;
      The results of this research project will elucidate the mechanism of the effect of using OCA&#xD;
      therapeutically in patients with PBC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by&#xD;
      cholestasis and cirrhosis. Pathogenesis comprises impaired hepatobiliary secretion of bile&#xD;
      acids to the bile. As a result bile flow reduces and diminished content of bile acids in the&#xD;
      intestines leads to impaired absorption of lipids and lipid-soluble vitamins, diarrhea,&#xD;
      general pruritus, and fatigue.&#xD;
&#xD;
      Bile acids are transported from blood to hepatocytes by the transporter proteins&#xD;
      Na+-taurocholate co-transporting polypeptide (NTCP) and Organic anion-transporting&#xD;
      polypeptide (OATP) and secreted from hepatocyte to bile canaliculi by the Bile salt export&#xD;
      pump (BSEP) and Multidrug resistance protein type 3 (MDR3). Dysfunction of BSEP most probably&#xD;
      plays a key pathogenic role in PBC.&#xD;
&#xD;
      Ursodeoxycholic acid (UDCA) is a dihydroxylated bile acid and the only approved drug for&#xD;
      treatment of PBC today. In most cases UDCA can delay or prevent disease progression. However,&#xD;
      a subgroup of patients does not respond adequately to UDCA and for these patients new&#xD;
      therapies are needed.&#xD;
&#xD;
      BSEP is induced by the nuclear bile acid receptor (BAR), also known as farnesoid X receptor&#xD;
      (FXR). Obeticholic Acid (INT-747, Intercept) (OCA) is a FXR agonist and induces BSEP.&#xD;
&#xD;
      OCA administration therefore may increase the hepatobiliary secretion of bile acids, being&#xD;
      the mechanism behind beneficial therapeutic effects in PBC.&#xD;
&#xD;
      Cholylsarcosine is a synthetic conjugated bile acid (sarcosine = methyl-glycine) that is&#xD;
      non-toxic, not metabolized in the gut or liver, and transported by BSEP. The trans-hepatic&#xD;
      transport of bile acids can be assessed in humans by PET/CT of the liver using 11C-labeled&#xD;
      cholylsarcosine (11C-CSar) as tracer. 11C-CSar is handled by the liver as a natural bile acid&#xD;
      in pig studies (1). Studies in humans (2) show that&#xD;
&#xD;
        -  11C-CSar is taken up avidly by the liver and flow-determined&#xD;
&#xD;
        -  11C-CSar secretion from hepatocytes to bile is reduced during cholestasis, and&#xD;
&#xD;
        -  11C-CSar back flux from hepatocytes to blood during cholestasis&#xD;
&#xD;
      Patients&#xD;
&#xD;
      8 patients with PBC&#xD;
&#xD;
        -  who are not responding adequately to treatment with UDCA, defined as ALP &gt; 2 times upper&#xD;
           normal level during a time period of 6 months&#xD;
&#xD;
        -  Patients are recruited from Aarhus University Hospital, Department of Hepatology and&#xD;
           Gastroenterology.&#xD;
&#xD;
      Paired study design&#xD;
&#xD;
        -  11C-CSar PET/CT before and after 3 months treatment with OCA or placebo.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      PET/CT: Initial low-dose CT for anatomical definition of the PET findings and for attenuation&#xD;
      correction of PET data. Dynamic 60-min PET recording of the tissue radioactivity&#xD;
      concentration over time following iv bolus injection of 100 MBq 11C-CSar and iv infusion of&#xD;
      100 MBq 11C-CSar. During the PET study, ICG is given as a constant iv infusion for&#xD;
      measurements of hepatic blood flow, used in the kinetic analysis, and blood samples are&#xD;
      collected from catheters in a radial artery and a liver vein (blood 11C-CSar concentrations&#xD;
      for kinetic calculations, ICG, and blood gasses for monitoring purposes).&#xD;
&#xD;
      Liver tests at the time points of the PET/CT study: Plasma ALT, ALP, GGT, bilirubin, bile&#xD;
      salts, IRN, platelets, hemoglobin, mitochondrial antibodies; ICG clearance.&#xD;
&#xD;
      Raw data comprise time-courses of the 11C-CSar concentrations in liver tissue and common&#xD;
      hepatic bile duct (PET recordings) and blood concentrations of 11C-CSar in arterial and liver&#xD;
      vein blood (blood samples); hepatic blood flow, hepatic venous pressure gradient (HVPG),&#xD;
      splanchnic oxygen uptake.&#xD;
&#xD;
      11C-CSar data comprise clearances of 11C-CSar from blood-to-hepatocytes and from&#xD;
      hepatocytes-to-bile canaliculi, vascular extraction fractions, biliary secretion fraction,&#xD;
      transit times, etc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2016</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blind placebo-controlled crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Codes (OCA or placebo) will be opened after final examination of final patient</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of OCA on bile flow</measure>
    <time_frame>Measured after 3 months of treatment with Obeticholic Acid or placebo</time_frame>
    <description>Bile flow measured by PET</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Obeticholic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic acid</intervention_name>
    <description>Placebo-controlled</description>
    <arm_group_label>Obeticholic Acid</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>placebos</arm_group_label>
    <other_name>Obeticholic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with PBC&#xD;
&#xD;
          -  who are not responding adequately to treatment with UDCA, defined as ALP &gt; 2 times&#xD;
             upper normal level during a time period of 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Itching that requires medical treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Keiding, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Susanne Keiding</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Ã˜rntoft NW, Munk OL, Frisch K, Ott P, Keiding S, SÃ¸rensen M. Hepatobiliary transport kinetics of the conjugated bile acid tracer (11)C-CSar quantified in healthy humans and patients by positron emission tomography. J Hepatol. 2017 Aug;67(2):321-327. doi: 10.1016/j.jhep.2017.02.023. Epub 2017 Feb 27.</citation>
    <PMID>28249726</PMID>
  </results_reference>
  <results_reference>
    <citation>SÃ¸rensen M, Munk OL, Ã˜rntoft NW, Frisch K, Andersen KJ, Mortensen FV, Alstrup AK, Ott P, Hofmann AF, Keiding S. Hepatobiliary Secretion Kinetics of Conjugated Bile Acids Measured in Pigs by 11C-Cholylsarcosine PET. J Nucl Med. 2016 Jun;57(6):961-6. doi: 10.2967/jnumed.115.171579. Epub 2016 Mar 10.</citation>
    <PMID>26966160</PMID>
  </results_reference>
  <results_reference>
    <citation>Frisch K, Jakobsen S, SÃ¸rensen M, Munk OL, Alstrup AK, Ott P, Hofmann AF, Keiding S. [N-methyl-11C]cholylsarcosine, a novel bile acid tracer for PET/CT of hepatic excretory function: radiosynthesis and proof-of-concept studies in pigs. J Nucl Med. 2012 May;53(5):772-8. doi: 10.2967/jnumed.111.098731. Epub 2012 Mar 27.</citation>
    <PMID>22454486</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bile Acid Transporter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

